Worldwide Clinical Trials
Worldwide Clinical Trials
Explore linked clinical trials.13 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label Study of XEN1101 in Epilepsy | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Tonic-Clonic Seizures, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Enrolling by invitation | Phase 3 | 2026-10-08 | NCT05718817 | |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 3 | 2026-10-08 | NCT05716100 | |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | brain disorder, central nervous system disorder, epilepsy, nervous system disorder | Recruiting | Phase 3 | 2026-10-08 | NCT05667142 | |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 3 | 2026-10-05 | NCT06793397 | |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Enrolling by invitation | Phase 3 | 2026-09-25 | NCT06605105 | |
| Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, urinary system disorder | Active, not recruiting | Phase 4 | 2026-09-24 | NCT06712407 | |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-08-03 | NCT06547489 | |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-07-27 | NCT07115329 | |
| A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) | Abnormalities, Multiple, Alzheimer disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Down syndrome, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, chromosomal disorder, cognitive disorder, dementia, hereditary disease, intellectual disability, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 1 / Phase 2 | 2026-07-10 | NCT05462106 | |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Genomic Instability, Microsatellite Instability, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Werner syndrome, hereditary disease, metabolic disease | Recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT06898450 | |
| A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, female reproductive system disorder, female reproductive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, uterine cancer, uterine disorder | Not yet recruiting | Phase 1 | 2026-04-21 | NCT07542704 | |
| A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-04-15 | NCT04762069 | |
| NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking) | Cognition Disorders, Cognitive Dysfunction, Lewy body dementia, Mild Cognitive Impairment, Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, dementia, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, psychiatric disorder, synucleinopathy | Active, not recruiting | Phase 2 | 2022-10-27 | NCT04148391 |